Global Orthobiologics Market – Analysis, Size, Share, Trends and Forecast, 2016 – 2022

Select Your License Type


Fig. Global Orthobiologics Market Projection

The market for global orthobiologics was valued at around USD 4.9 billion in 2015 and is expected to reach USD 6.5 billion by 2022, growing at a CAGR of around 4.1% during the forecast period of 2016 to 2022. Orthobiologics are substances that orthopaedic surgeons use to help injuries heal more quickly. They are used to improve the healing of broken bones and injured muscles, tendons, and ligaments. These products are made from substances that are naturally found in your body.  Anything that is concerned with muscles, ligaments and joints is considered orthopedic. Disorders are ailments, injuries or diseases that cause knee problems, whiplash, dislocated shoulder, torn cartilages, foot pain and fibromyalgia. These are only a few of the known orthopedic disorders. There are as many treatments for orthopedic disorders as there are problems and injuries in the muscles, ligaments and joints. Orthopedic treatments and devices have helped restore a normal lifestyle for millions of patients globally.

The increasing incidence of sports injuries, osteoarthritis, osteoporosis, and obesity, combined with the ever-increasing aging population globally is the key growth drivers of the global orthobiologics market. Along with these factors, increasing R&D investments and collaborations between leading medical device and biotechnology companies, leading to advent of advanced orthobiologics is expected to increase the base for growth of orthobiologics.

Geographically, North America is the leading contributor to the market and is expected to retain its position during the forecast period due to the presence of large number of orthopedic patients and rise in base of aging population. However, Asia-Pacific market is expected to grow at a faster rate during the forecast period. This is predominantly due to increased healthcare awareness, improved economic growth, joint ventures and some significant mergers and acquisitions and increased government funding.

Companies profiled:

  • Medtronic Plc
  • Sanofi
  • DePuy Synthes
  • Stryker Corporation
  • Integra Lifesciences
  • NuVasive
  • Smith & Nephew plc
  • Bioventus LLC
  • Wright Medical Technology
  • Zimmer Biomet

Report Highlights:

The report delivers a strategic analysis of the global market for orthobiologic products and growth forecast for the period from 2016 – 2022. The scope of the report includes competitive analysis of various market players who are operating in the market, segmental analysis based on type of disorder. It also covers geographical analysis of the market with growth forecast for the period of 2016 – 2022. The Porter’s Five Forces analysis and value chain analysis included in the report provides an insight into market dynamics and industry competition.

Moreover, the report also includes growth strategies and entry barriers to be considered to cater to the exact business opportunities in this market. Additionally, to aid in strategic decision making, the report also includes competitive profiling of leading players, recent developments in the industry and various business strategies adopted by them. This report will help players in global orthobiologics market to plan and implement their strategies in different market areas such as emerging geographies, and new technologies

1. Scope of the report

1.1 Report description
1.2 Research methodology
1.3 List of abbreviations
1.4 Market segmentation

2 Executive summary
3 Qualitative analysis

3.1 Market overview

3.1.1 Drivers
3.1.2 Restraints

3.2 Epidemiology
3.3 Porters five forces analysis
3.4 Market share analysis of key players, 2015
3.5 Competitive matrix of the key companies

4 Global orthobiologics market, by type, 2015 – 2022

4.1 Allografts
4.2 Demineralised bone matrix
4.3 Bone morphogenic proteins
4.4 Synthetic bone grafts
4.5 Joint fluid therapy (Viscosupplementation)
4.6 Stem cell therapies
4.7 Soft tissue repair

5 Global orthobiologics market, by geography, 2015 – 2022

5.1 North America

5.1.1 Allografts
5.1.2 Demineralised bone matrix
5.1.3 Bone morphogenic proteins
5.1.4 Synthetic bone grafts
5.1.5 Joint fluid therapy (Viscosupplementation)
5.1.6 Stem cell therapies
5.1.7 Soft tissue repair

5.2 Europe

5.2.1 Allografts
5.2.2 Demineralised bone matrix
5.2.3 Bone morphogenic proteins
5.2.4 Synthetic bone grafts
5.2.5 Joint fluid therapy (Viscosupplementation)
5.2.6 Stem cell therapies
5.2.7 Soft tissue repair

5.3 APAC

5.3.1 Allografts
5.3.2 Demineralised bone matrix
5.3.3 Bone morphogenic proteins
5.3.4 Synthetic bone grafts
5.3.5 Joint fluid therapy (Viscosupplementation)
5.3.6 Stem cell therapies
5.3.7 Soft tissue repair

5.4 Rest of the World

5.4.1 Allografts
5.4.2 Demineralised bone matrix
5.4.3 Bone morphogenic proteins
5.4.4 Synthetic bone grafts
5.4.5 Joint fluid therapy (Viscosupplementation)
5.4.6 Stem cell therapies
5.4.7 Soft tissue repair

6 Company profiles

6.1 Zimmer Biomet
6.2 DePuy Synthes
6.3 Stryker Corporation
6.4 Smith & Nephew plc
6.5 Wright Medical Group N.V.
6.6 Bioventus LLC
6.7 Sanofi S.A.
6.8 NuVasive, Inc.
6.9 Integra lifesciences,
6.10 Medtronic plc

Got a Question?

If you have a question to ask our analyst, just fill this form and send it across, our representative will get in touch with you shortly.